title: Rheology of cystic fibrosis sputum after in vitro treatment with hypertonic saline alone and in combination with recombinant human deoxyribonuclease I.
abstract: Treatment with recombinant human deoxyribonuclease I (rhDNase) is currently used as therapy for cystic fibrosis (CF) lung disease. Hypertonic saline (HS) acts as an expectorant promoting mucus secretion and augmenting the volume of sputum. We evaluated the individual and combined effects of HS and rhDNase in vitro on the viscoelasticity of CF sputum. Sputum samples were collected from nine CF patients to use for in vitro testing. Aliquots of CF sputum (0.20 to 0.40 g) were subjected to the following protocols: (1) negative control sample without any treatment; (2) positive control sample, adding 10% volume of normal saline (0.9% NaCl); (3) application of hypertonic saline (HS-3% NaCl); (4) combining approximately 100 nM concentration of rhDNase with protocols 2 and 3. The samples in protocols 2 through 4 were incubated for 30 min at 37 degrees C. For each protocol, CF sputum was analyzed at baseline and at 30 min for spinnability by filancemeter and viscoelasticity by magnetic microrheometry. Spinnability decreased for the sputum samples that were treated with rhDNase, in combination with either HS or normal saline. Treatment with HS alone and combined treatment with rhDNase and HS decreased log G* (the principal viscoelasticity index) to the same degree. Saline alone and rhDNase in normal saline both increased the predicted cough clearability of the sputum; however, the combined treatment with rhDNase and hypertonic saline had the best overall effect on cough clearability. The change in predicted mucociliary clearability, although greatest after HS, was not significant. These in vitro results suggest that combined treatment with rhDNase and HS should be evaluated further as a potential mucotropic approach to augment the clearance of purulent sputum in CF lung disease.
authors.affiliation: Pulmonary Research Group, University of Alberta, Edmonton, Canada. malcolm.king@ualberta.ca
authors.forename: M
authors.initials: M
authors.lastname: King
authors.forename: B
authors.initials: B
authors.lastname: Dasgupta
authors.forename: R P
authors.initials: RP
authors.lastname: Tomkiewicz
authors.forename: N E
authors.initials: NE
authors.lastname: Brown
mesh_terms: D000293:Adolescent; D000328:Adult; D003550:Cystic Fibrosis / Q000188:drug therapy / Q000503:physiopathology*; D003850:Deoxyribonuclease I / Q000494:pharmacology* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004548:Elasticity / Q000187:drug effects; D005100:Expectorants / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D066298:In Vitro Techniques; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D012212:Rheology / Q000187:drug effects*; D012462:Saline Solution, Hypertonic / Q000494:pharmacology* / Q000627:therapeutic use; D013183:Sputum / Q000187:drug effects* / Q000502:physiology; D014783:Viscosity / Q000187:drug effects
chemical_list: D005100:Expectorants; D011994:Recombinant Proteins; D012462:Saline Solution, Hypertonic; C085693:DNASE1 protein, human; D003850:Deoxyribonuclease I